HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HBW Market News: VSI Focuses On First Offer, Nestle Invests In Consumer Health, Eosera Adds Products, Space, Staff

Executive Summary

Vitamin Shoppe discloses preliminary plan for shareholder vote on $208m takeover offer; Nestle Health Science invests in SpoonfulOne early childhood food allergy prevention brand; and ear care product firm Eosera moves to facility twice as large and adds two products, four staff members.

You may also be interested in...



Nestle Harvests Plant-Based Protein Firm Orgain As Latest US Nutrition Business Investment

Nestle Health Science has expanded its nutritional footprint steadily since 2017 but investing in Orgain, with option to fully acquire in 2024 brings its first business working exclusively with plant-based ingredients.

Nestle Pairs Nutrition Science Business With Pharma Firm Making Peanut Allergy Treatment

Nestle agrees to acquire Aimmune Therapeutics, maker of a drug indicated to reduce the severity of children’s allergic reactions to peanuts. It anticipates options to innovate in its consumer health children’s allergy business.

OTC Ear Care Firm Eosera Gets Earful From US FDA On Pain And Itch Remedies, GMP Compliance

Eosera has removed its Ear Pain MD and Ear Itch MD products from e-commerce pages on its website following FDA's warning letter. The warning identifying the pain and itch products as unapproved new drugs also states that a January inspection of the firm’s facility found GMP violations. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149262

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel